Gilead’s Captisol-enabled Remdesivir Approved for Use in Renally Impaired Patients
Read full release and find prescribing information
Gilead’s Captisol-enabled Remdesivir Approved for Use in Renally Impaired Patients
Read full release and find prescribing information
"Currently, between 70 and 90% of drug candidates in pipelines are believed to have low solubility. In fact, poor solubility problems is considered to be the leading challenge in drug development"
- Chemical Engineering News 2010
Captisol® enables the creation of new products by significantly improving solubility, stability, bioavailability, safety and dosing of active pharmaceutical ingredients (APIs).
Captisol® is a circular-shaped molecule with a hydrophilic exterior surface and hydrophilic interior cavity. The hydrophilic surface generates good water solubility and a relatively hydrophobic interior cavity provides a favorable environment for water insoluble drug molecules.
